(Corrects paragraph 5 in February 5 story to say 2025 Prolia sales were $4.4 billion, not $1.05 billion) Feb 5 (Reuters) - CVS Health said on Thursday it would swap out Amgen and Eli Lilly's bone ...
Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen ...
Treatment strategies after denosumab discontinuation in non-metastatic breast cancer treated with AI
This narrative review by an expert International Osteoporosis Foundation (IOF) Working Group highlights an under-recognized bone health risk in women with early-stage, hormone receptor–positive breast ...
--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...
Enoby and Xtrenbo are FDA-approved biosimilars for denosumab, providing cost-effective alternatives to Prolia and Xgeva for cancer patients. Enoby targets bone loss in patients on hormone-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results